Skip to main content

Table 5 A subgroup analysis of the relationship between three MiRNA polymorphisms and susceptibility to cervical cancer

From: Association of three micro-RNA gene polymorphisms with the risk of cervical cancer: a meta-analysis and systematic review

Variable

No.

CC vs. GG

CG vs. GG

CG+CC vs. GG

CC vs. GG+CG

CC+GG vs. CG

C vs. G

MiRNA-146a rs2910164

OR [95% CI]

P

OR [95% CI]

P

OR [95% CI]

P

OR [95% CI]

P

OR [95% CI]

P

OR [95% CI]

P

PCR-RFLP*

4

0.626 [0.453-0.865]

0.004

0.787 [0.637-0.972]

0.026

0.726 [0.590-0.893]

0.002

0.753 [0.581-0.976]

0.032

0.986 [0.835-1.164]

0.866

0.795 [0.681-0.928]

0.004

TaqMan

1

1.015 [0.786-1.311]

0.908

1.132 [0.887-1.445]

0.320

1.082 [0.858-1.364]

0.505

0.924 [0.775-1.102]

0.379

0.893 [0.755-1.056]

0.185

0.984 [0.872-1.111]

0.798

China

4

0.715 [0.477-1.072]

0.105

0.921 [0.779-1.089]

0.334

0.796 [0.584-1.048]

0.148

0.813 [0.641-1.031]

0.088

0.935 [0.828-1.056]

0.278

0.849 [0.706-1.021]

0.083

India

1

0.684 [0.358-1.309]

0.252

0.913 [0.549-1.516]

0.724

0.830 [0.527-1.305]

0.419

0.709 [0.382-1.315]

0.276

1.000 [0.617-1.620]

1.000

0.809 [0.574-1.138]

0.223

MiRNA-499 rs3746444

CC vs. TT

CT vs. TT

CT+CC vs. TT

CC vs. CT+TT

TT+CC vs. CT

C vs. T

PCR-RFLP*

2

0.843 [0.497-1.430]

0.527

1.326 [0.555-3.164]

0.525

1.258 [0.587-2.696]

0.555

0.893 [0.598-1.333]

0.579

0.721 [0.347-1.496]

0.379

1.159 [0.733-1.832]

0.528

TaqMan

1

1.081 [0.648-1.803]

0.765

0.943 [0.776-1.145]

0.552

0.956 [0.792-1.152]

0.634

1.098 [0.660-1.827]

0.720

1.064 [0.877-1.292]

0.531

0.975 [0.827-1.149]

0.762

China

2

1.028 [0.661-1.600]

0.902

1.337 [0.650-2.748]

0.430

1.278 [0.695-2.349]

0.429

0.983 [0.634-1.524]

0.939

0.746 [0.359-1.549]

0.432

1.165 [0.789-1.720]

0.443

India

1

0.819 [0.424-1.582]

0.552

0.806 [0.398-1.630]

0.548

0.814 [0.433-1.529]

0.522

0.948 [0.602-1.492]

0.817

1.063 [0.654-1.727]

0.805

0.911 [0.645-1.287]

0.597

MiRNA-196a2 rs11614913

TT vs. CC

CT vs. CC

CT+TT vs. CC

TT vs. CT+CC

TT+CC vs. CT

T vs. C

PCR-RFLP*

2

0.388 [0.076-1.970]

0.253

0.788 [0.559-1.110]

0.173

0.597 [0.261-1.365]

0.221

0.449 [0.103-1.956]

0.286

0.939 [0.711-1.239]

0.655

0.589 [0.230-1.505]

0.268

TaqMan

3

0.762 [0.625-0.929]

0.007

0.937 [0.804-1.092]

0.404

0.872 [0.755-1.008]

0.064

0.807 [0.707-0.921]

0.001

0.921 [0.818-1.037]

0.176

0.871 [0.795-0.955]

0.003

PCR-LDR*

1

0.886 [0.448-1.751]

0.727

1.178 [0.625-2.220]

0.613

1.049 [0.578-1.901]

0.876

0.791 [0.471-1.326]

0.373

0.788 [0.487-1.276]

0.333

0.915 [0.650-1.288]

0.612

China

5

0.787 [0.672-0.921]

0.003

0.946 [0.822-1.089]

0.439

0.884 [0.773-1.010]

0.069

0.817 [0.724-0.923]

0.001

0.922 [0.827-1.029]

0.148

0.883 [0.817-0.954]

0.002

India

1

0.167 [0.086-0.323]

<0.001

0.637 [0.374-1.085]

0.097

0.389 [0.241-0.628]

<0.001

0.209 [0.114-0.381]

<0.001

0.817 [0.510-1.309]

0.401

0.362 [0.259-0.506]

<0.001

  1. Note: PCR-RFLP restriction fragment length polymorphism polymerase chain reaction, PCR-LDR polymerase chain reaction-ligase detection reaction
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us